- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06910969
Multidisciplinær indgriben for voksne med kronisk transplantat-mod-vært sygdom (HORIZONS)
Multi-site randomiseret kontrolleret forsøg med en tværfaglig indgriben for voksne med kronisk transplantat versus værtssygdom
The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This is a randomized clinical trial to determine whether a multidisciplinary group-based telehealth intervention is effective at improving the quality of life and reducing psychosocial distress in patients living with chronic graft-versus-host disease. The HORIZONS intervention was developed with the goal of improving the experience and needs of patients living with chronic graft-versus-host disease.
Participants will be randomized into one of the two study groups: HORIZONS plus usual care or minimally enhanced usual care.
Participation in this study is expected to last up to 18 weeks after enrollment.
The investigators expect that about 350 adult allogeneic hematopoietic cell transplant recipients with moderate to severe chronic graft versus host disease will take part in this research study.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Lara Traeger PhD
- Telefonnummer: 304-284-3012
- E-mail: ltraeger@miami.edu
Undersøgelse Kontakt Backup
- Navn: Areej El-Jawahri MD
- Telefonnummer: 617-721-4000
- E-mail: ael-jawahri@mgb.org
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami Sylvester Comprehensive Cancer Center
-
Ledende efterforsker:
- Lara Traeger, PhD
-
Kontakt:
- Lara Traeger, PhD
- Telefonnummer: 305-243-5302
- E-mail: ltraeger@miami.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Ledende efterforsker:
- Areej El-Jawahri, MD
-
Kontakt:
- Areej El-Jawahri
- Telefonnummer: 617-724-4000
- E-mail: ael-jawahri@mgb.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult patients (≥ 18 years) who have undergone allogeneic HCT
- Have moderate to severe cGVHD based on patient-report
- Have ability to participate in English or Spanish language group telehealth intervention.
Exclusion Criteria:
- Patients with mild cGVHD based on their self-report.
- Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.
- Patients with active relapsed disease requiring therapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: HORIZONS intervention
Participants randomized to HORIZONS plus usual care will complete the following:
|
Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions |
|
Aktiv komparator: Minimally enhanced usual care
Participants randomized to usual care will complete the following
|
Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-BMT (FACT-BMT) questionnaire
Tidsramme: At 10 weeks post-enrollment
|
Compare patient QOL as measured by the FACT-BMT between the two study groups. The FACT-BMT ranges from 0-164 with higher scores indicating better QOL |
At 10 weeks post-enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient depression symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Depression)
Tidsramme: At 10 weeks post enrollment
|
Compare depression symptoms as measured by the HADS-Depression between the study groups. The HADS-Depression ranges from 0-21 with higher scores indicating worse depression symptoms |
At 10 weeks post enrollment
|
|
Patient anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Anxiety)
Tidsramme: At 10 weeks post enrollment
|
Compare anxiety symptoms as measured by the HADS-Anxiety between the study groups. The HADS-Anxiety ranges from 0-21 with higher scores indicating worse anxiety symptoms. |
At 10 weeks post enrollment
|
|
Patient chronic graft-versus-host disease symptoms as measured with the Lee Symptom Scale
Tidsramme: At 10 weeks post enrollment
|
Compare chronic graft versus host disease symptoms as measured by the Lee Symptom Scale. The Lee Symptom Scale ranges from 0 -100 with higher scores indicating worse symptomatology |
At 10 weeks post enrollment
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Areej El-Jawahri MD, Massachusetts General Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 24-651
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The Dana Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Areej El-Jawahri (ael-jawahri@mgb.org). The protocol and statistical analysis plan will be made available on Clinicaltrials.gov as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Data can be shared no earlier than 1 year following the date of publication
IPD-delingsadgangskriterier
Contact the Partners Innovations team at http://www.partners.org/innovation
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .